Arvinas, Inc. (ARVN) Presents at Wells Fargo 20th Annual Healthcare

Overview - The company is experiencing a significant year of change and transition, with a focus on pivotal data for a PROTAC, specifically vepdegestrant [1]. Company Developments - The first pivotal data for vepdegestrant was positive, marking a milestone for the company [1]. - Despite the positive data, the market reaction was disappointing, particularly from Pfizer, indicating that the results were not positive enough to meet expectations [1][2]. - The decline in stock price following the data release has prompted the company to consider several next steps in response to the market's reaction [2].